ReviewBiomedicines2023
The Potential Role of C-Reactive Protein in Metabolic-Dysfunction-Associated Fatty Liver Disease and Aging.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Article
- A Nomogram Integrating CD169%, Neutrophil CD64 Index, and C-Reactive Protein for Differential Diagnosis of Mixed Respiratory Tract Infections.Diagnostics (Basel, Switzerland) · 2026Article
- Association between metabolic signatures of predicted VAT mass and risk of MASLD and other chronic liver diseases.International journal of obesity (2005) · 2026Article
- Dietary folate intake and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.Nutrition & metabolism · 2026Article
- Article
- Application of Multivariate Adaptive Regression Splines to Estimate Fatty Liver Index in Healthy Young Taiwanese Men.Diagnostics (Basel, Switzerland) · 2026Article
- Obesity, Metabolic Syndrome and MASLD in Children: Inflammation as the Missing Link-A Short Narrative Review.Life (Basel, Switzerland) · 2026Review
- Remnant cholesterol inflammatory index and MASLD in U.S. adults: mediation role of triglyceride-glucose index.Journal of clinical & translational endocrinology · 2026Article
- Biomarkers for early identification of metabolic dysfunction-associated steatotic liver disease (MASLD): a narrative review.Archives of medical science : AMS · 2026Article
- Heterochronic parabiosis alters the transcriptomic landscape to combat aging and aging-related diseases in aging-accelerated mice.Life medicine · 2025Article
- Lipid profile and non-alcoholic fatty liver disease detected by ultrasonography: is systemic inflammation a necessary mediator?Annals of medicine · 2025Article
- Article
- The Diagnostic Potential and Regulatory Mechanisms of miR-3180-3p in Metabolic Dysfunction-Associated Fatty Liver Disease with Respect to Inflammation and Oxidative Stress.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Prognostic value of dynamic changes in C-reactive protein to albumin ratio in patients with acute-on-chronic liver failure.World journal of hepatology · 2025Article
- Macrophage and inflammation in diabetes and metabolic dysfunction-associated steatotic liver disease: From mechanisms to therapeutic strategies.World journal of diabetes · 2025Review
- Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation.Medical sciences (Basel, Switzerland) · 2025Review
- Pan-immune-inflammation value and mortality in the US adult MASLD: a nonlinear NHANES analysis.BMC gastroenterology · 2025Article
- Prognostic impact of systemic inflammation indicators on all-cause and CVD mortality in adults with MASLD.BMC gastroenterology · 2025Article
- Cardiometabolic diseases in patients with inflammatory bowel disease: An evidence-based review.World journal of gastroenterology · 2025Review
- Correlation between hs-CRP-triglyceride glucose index and NAFLD and liver fibrosis.BMC gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD), recently redefined as metabolic-dysfunction-associated fatty liver disease (MASLD), is liver-metabolism-associated steatohepatitis caused by nonalcoholic factors. NAFLD/MASLD is currently the most prevalent liver disease in the world, affecting one-fourth of the global population, and its prevalence increases with age. Current treatments are limited; one important reason hindering drug development is the insufficient understanding of the onset and pathogenesis of NAFLD/MASLD. C-reactive protein (CRP), a marker of inflammation, has been linked to NAFLD and aging in recent studies. As a conserved acute-phase protein, CRP is widely characterized for its host defense functions, but the link between CRP and NAFLD/MASLD remains unclear. Herein, we discuss the currently available evidence for the involvement of CRP in MASLD to identify areas where further research is needed. We hope this review can provide new insights into the development of aging-associated NAFLD biomarkers and suggest that modulation of CRP signaling is a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.